Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 79,3 M
EBIT 2017 7,39 M
Net income 2017 -2,93 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 119 M
EBIT 2018 18,5 M
Net income 2018 7,12 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 56,67
EV / Sales2017 5,26x
EV / Sales2018 3,49x
Capitalization 345 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
03/06Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
10/02 Teligent, Inc. Announces FDA Approval of Partnered ANDA for Desonide Lotion, ..
09/20 TELIGENT : Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
09/19 Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0..
09/18 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Departure of Directors or Certain Of..
09/18 TELIGENT, INC. : Change in Directors or Principal Officers, Other Events, Financ..
09/18 Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
09/12 Teligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare Con..
08/23 TELIGENT : Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emo..
08/22 TELIGENT : Receives Fourth FDA Approval on 2017
08/22 Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.0..
More news
Sector news : Pharmaceuticals - NEC
03:13pDJEuropean Corporate Roundup for Monday
02:26pDJDrug Makers Find 'Branded Generics' Are a Source for Growth
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
11:08a European shares flat as banks weigh, Spain lags again
11:03aDJEuropean Corporate Roundup for Monday
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,40 $
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI345
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223